Welcome to the CAH Support Group’s new website!
Welcome to our new website – we hope you like it!
We’d like to thank the Society for Endocrinology and Midas Creative for their support in making it happen.
We’ve got big plans for our new site and this is just the beginning…Over the new few months we’ll be opening our members’ only forum, and adding some news articles about what the Group’s committee members have been up to. Next year, we hope to add even more features…
If you’ve any questions or comments, please let us know through the Contact Us page.
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...
0 Comments